Riskpilot← Back to searchSign inGet full accessEyeMind AB
ABActiveOrg 5590512678Inedalsgatan 9 CMedical specialists activities · NACE 8622Est. 20161 employees
Revenue 2025
SEK 1,5M
+14% vs 2024
EBITDA margin
20.3%
+33% vs 2024
Equity ratio
48.8%
Financial strength
Net profit 2025
SEK -11K
-105% vs 2024
| Revenue | SEK 1,5M | +14% |
| EBITDA | SEK 311K | +33% |
| Net profit | SEK -11K | -105% |
| Total assets | SEK 643K | -21% |
| Equity | SEK 314K | -40% |
| Employees | 1 | — |
Legal name
EyeMind AB
Org number
5590512678
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
15 februari 2016
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget bedriver läkarvård inom ögonsjukdomar och ögonplastikkirurgi. Bolaget erbjuder även övrig medicinsk konsultverksamhet, rådgivning, handledning och undervisning. Företaget tillhandahåller bemanning inom utbildning på grundskolenivå och läxhjälp.
Address
Inedalsgatan 9 C
Email
info@eyemind.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 699 | 1 072 | 1 397 | 1 345 | 1 528 |
| Staff expenses | — | — | — | −987 | −824 |
| EBITDA | −279 | 167 | 327 | 234 | 311 |
| Depreciation & amort. | −0 | −0 | −0 | — | — |
| EBIT | −279 | 167 | 327 | 234 | 70 |
| Net financials | — | −2 | 2 | 3 | 0 |
| Profit before tax | −19 | 166 | 330 | 272 | 115 |
| Tax | −1 | −39 | −71 | −59 | −126 |
| Net profit | −20 | 127 | 259 | 213 | −11 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 793 | 779 | 899 | 814 | 643 |
| Equity | 326 | 453 | 512 | 525 | 314 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 297 | 156 | 217 | 154 | 239 |
| Total debt | 297 | 156 | 217 | 154 | 239 |
EBITDA margin
20.3%
This company
15.8%
Market median
+28% vs market
20212025
Equity ratio
48.8%
This company
38.2%
Market median
+28% vs market
20212025
Return on equity
-3.5%
This company
18.4%
Market median
-119% vs market
20212025
Net profit margin
-0.7%
This company
8.1%
Market median
-109% vs market
20212025
Asset turnover
2.38×
This company
1.12×
Market median
+112% vs market
20212025
Debt / equity
1.05×
This company
0.62×
Market median
-69% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
RT Chief Executive Officer | Chief Executive Officer | 2022 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
| Former (2) | ||
| Deputy Board Member | 2022 – 2022 | |
| Deputy Board Member | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of EyeMind AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rozbeh Tavosian | Chief Executive Officer | 0 companies |
| Lily Nazli Tavosian | Deputy Board Member | 0 companies |
| Bianca Margareta Sand | Deputy Board Member | 0 companies |
| Pari Sima Soltan Pour | Deputy Board Member | 0 companies |